HCPCS Code Details - G9562

HCPCS Level II Code
Procedures/Professional Services (Temporary Codes)
HCPCS Code G9562
Description

Long description:
Patients who had a follow-up evaluation conducted at least every three months during opioid therapy

Short description:
Foll-up eval q3mo opiod tx

HCPCS Modifier1
HCPCS Pricing indicator 00 - Physician Fee Schedule And Non-Physician Practitioners - Service not separately priced by part B (e.g., services not covered, bundled, used by Part A only, etc.)
Multiple pricing indicator 9 - Not applicable as HCPCS not priced separately by part B or value is not established
Coverage code C - Carrier judgment
BETOS2 code Z2 - Undefined codes
HCPCS Action code N - No maintenance for this code
Type of service 1 - Medical care
Effective date Effective Jan 01, 2022
Date added Added Jan 01, 2016
Termination date Dec 31, 2021
HCPCS Coding Procedures

HCPCS Modifiers

In HCPCS Level II, modifiers are composed of two alpha or alphanumeric characters.

Example: E0260-NU - Hospital bed, semi-electric (head and foot adjustment), with any type side rails, with mattress
NU” identifies the hospital bed as new equipment

See also

  • HCPCS G9561 · Patients prescribed opiates for longer than six weeks

  • HCPCS G9301 · Patients who had the prophylactic antibiotic completely infused prior to the inflation of the proximal tourniquet

  • HCPCS G9724 · Patients who had documentation of use of anticoagulant medications overlapping the measurement year

  • HCPCS G9822 · Patients who had an endometrial ablation procedure during the 12 months prior to the index date (exclusive of the index date)

  • HCPCS M1262 · Patients who had a transplant prior to initiation of dialysis

  • HCPCS M1319 · Patients who had documented contact with a csp for at least one of their screened positive hrsns within 60 days after screening

  • HCPCS M1324 · Patients who had an intravitreal or periocular corticosteroid injection (e.g., triamcinolone, preservative-free triamcinolone, dexamethasone, dexamethasone intravitreal implant, or fluocinolone intravitreal implant)

  • HCPCS M1338 · Patients who had follow-up assessment 30 to 180 days after the index assessment who did not demonstrate positive improvement or maintenance of functioning scores during the performance period

  • HCPCS M1339 · Patients who had follow-up assessment 30 to 180 days after the index assessment who demonstrated positive improvement or maintenance of functioning scores during the performance period

  • HCPCS M1345 · Patients who had a baseline pam score and a second score within 6 to 12 month of baseline pam score

  • HCPCS M1350 · Patients who had a completed suicide safety plan initiated, reviewed or updated in collaboration with their clinician (concurrent or within 24 hours) of the index clinical encounter

  • HCPCS M1351 · Patients who had a suicide safety plan initiated, reviewed, or updated and reviewed and updated in collaboration with the patient and their clinician concurrent or within 24 hours of clinical encounter and within 120 days after initiation

  • HCPCS M1357 · Patients who had a reduction in suicidal ideation and/or behavior upon follow-up assessment within 120 days of index assessment

  • HCPCS G9563 · Patients who did not have a follow-up evaluation conducted at least every three months during opioid therapy


1 Two-digit numeric codes are Level I code modifiers copyrighted© by the American Medical Association's Current Procedural Terminology (CPT).

2 BETOS stands for “Berenson-Eggers Type Of Service”